Peter Mundel1, Anna Greka. 1. aDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School bDepartment of Medicine, Glom-NExT Center for Glomerular Kidney Disease and Novel Experimental Therapeutics, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: A core mission for modern medicine is the development of precision therapeutics. Cancer therapies have been at the leading edge of this effort, while nephrology has lagged on the path to precision medicine. Breaking the stalemate, recent work revealed CD80 (B7-1) as a candidate for targeted therapy in the treatment of resistant nephrotic syndrome. This review aims to summarize the current state of our understanding of podocyte CD80 biology, its therapeutic implications and the challenges that lie ahead in essential future validation studies. RECENT FINDINGS: The CD80 targeting agent abatacept (CTLA4-Ig), approved to treat rheumatoid arthritis, was shown to induce remission of nephrotic range proteinuria in four patients with recurrence of disease posttransplant and one patient with primary, treatment resistant nephrotic syndrome. The concept of 'CD80-positive' proteinuric kidney disease due to podocyte CD80 staining in patient kidney biopsies was introduced as a molecular biomarker to define disease and guide treatment. The mechanism of action of CTLA4-Ig in podocytes was shown to centre on β1 integrin activation in a T-cell independent fashion. Subsequent work revealed a putative role for podocyte CD80 in diabetic kidney disease. SUMMARY: These studies have direct implications for patient care, and intense interest has focused on validating these findings in upcoming clinical trials.
PURPOSE OF REVIEW: A core mission for modern medicine is the development of precision therapeutics. Cancer therapies have been at the leading edge of this effort, while nephrology has lagged on the path to precision medicine. Breaking the stalemate, recent work revealed CD80 (B7-1) as a candidate for targeted therapy in the treatment of resistant nephrotic syndrome. This review aims to summarize the current state of our understanding of podocyte CD80 biology, its therapeutic implications and the challenges that lie ahead in essential future validation studies. RECENT FINDINGS: The CD80 targeting agent abatacept (CTLA4-Ig), approved to treat rheumatoid arthritis, was shown to induce remission of nephrotic range proteinuria in four patients with recurrence of disease posttransplant and one patient with primary, treatment resistant nephrotic syndrome. The concept of 'CD80-positive' proteinuric kidney disease due to podocyte CD80 staining in patient kidney biopsies was introduced as a molecular biomarker to define disease and guide treatment. The mechanism of action of CTLA4-Ig in podocytes was shown to centre on β1 integrin activation in a T-cell independent fashion. Subsequent work revealed a putative role for podocyte CD80 in diabetic kidney disease. SUMMARY: These studies have direct implications for patient care, and intense interest has focused on validating these findings in upcoming clinical trials.
Authors: Chih-Chuan Yu; Alessia Fornoni; Astrid Weins; Samy Hakroush; Dony Maiguel; Junichiro Sageshima; Linda Chen; Gaetano Ciancio; Mohd Hafeez Faridi; Daniel Behr; Kirk N Campbell; Jer-Ming Chang; Hung-Chun Chen; Jun Oh; Christian Faul; M Amin Arnaout; Paolo Fiorina; Vineet Gupta; Anna Greka; George W Burke; Peter Mundel Journal: N Engl J Med Date: 2013-11-08 Impact factor: 91.245
Authors: Paolo Fiorina; Andrea Vergani; Roberto Bassi; Monika A Niewczas; Mehmet M Altintas; Marcus G Pezzolesi; Francesca D'Addio; Melissa Chin; Sara Tezza; Moufida Ben Nasr; Deborah Mattinzoli; Masami Ikehata; Domenico Corradi; Valerie Schumacher; Lisa Buvall; Chih-Chuan Yu; Jer-Ming Chang; Stefano La Rosa; Giovanna Finzi; Anna Solini; Flavio Vincenti; Maria Pia Rastaldi; Jochen Reiser; Andrzej S Krolewski; Peter H Mundel; Mohamed H Sayegh Journal: J Am Soc Nephrol Date: 2014-03-27 Impact factor: 10.121
Authors: Jochen Reiser; Gero von Gersdorff; Martin Loos; Jun Oh; Katsuhiko Asanuma; Laura Giardino; Maria Pia Rastaldi; Novella Calvaresi; Haruko Watanabe; Karin Schwarz; Christian Faul; Matthias Kretzler; Anne Davidson; Hikaru Sugimoto; Raghu Kalluri; Arlene H Sharpe; Jordan A Kreidberg; Peter Mundel Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Marta Christov; Abbe R Clark; Braden Corbin; Samy Hakroush; Eugene P Rhee; Hiroaki Saito; Dan Brooks; Eric Hesse; Mary Bouxsein; Niels Galjart; Ji Yong Jung; Peter Mundel; Harald Jüppner; Astrid Weins; Anna Greka Journal: JCI Insight Date: 2018-02-22
Authors: Jonas Sieber; Nicolas Wieder; Abbe Clark; Manuel Reitberger; Sofia Matan; Jeannine Schoenfelder; Jianming Zhang; Anna Mandinova; Joshua Adam Bittker; Juan Gutierrez; Ozan Aygün; Namrata Udeshi; Steven Carr; Peter Mundel; Andreas Werner Jehle; Anna Greka Journal: Cell Chem Biol Date: 2017-12-14 Impact factor: 8.116
Authors: Marianne Delville; Emilie Baye; Antoine Durrbach; Vincent Audard; Tomek Kofman; Laura Braun; Jérôme Olagne; Clément Nguyen; Georges Deschênes; Bruno Moulin; Michel Delahousse; Gwenaëlle Kesler-Roussey; Séverine Beaudreuil; Frank Martinez; Marion Rabant; Philippe Grimbert; Morgan Gallazzini; Fabiola Terzi; Christophe Legendre; Guillaume Canaud Journal: J Am Soc Nephrol Date: 2015-12-23 Impact factor: 10.121
Authors: Sung Woo Lee; Seon Ha Baek; Jin Ho Paik; Sejoong Kim; Ki Young Na; Dong-Wan Chae; Ho Jun Chin Journal: Sci Rep Date: 2017-02-02 Impact factor: 4.379
Authors: Howard Trachtman; Debbie S Gipson; Michael Somers; Cathie Spino; Sharon Adler; Lawrence Holzman; Jeffrey B Kopp; John Sedor; Sandra Overfield; Ayanbola Elegbe; Michael Maldonado; Anna Greka Journal: Kidney Int Rep Date: 2017-08-31